Influenza — Diagnosis and Management

Influenza is an acute viral respiratory infection caused by orthomyxoviruses (influenza A, B, and C), characterized by abrupt onset of fever, myalgias, and respiratory symptoms. Clinically significant as a major cause of seasonal morbidity and mortality, with epidemic and pandemic potential, particularly in vulnerable populations including the elderly, pregnant women, immunocompromised individuals, and those with chronic cardiopulmonary disease. Annual influenza epidemics affect 5–20% of the population in temperate regions, resulting in 200,000 hospitalizations and 3,000–49,000 deaths annually in the United States alone. Understanding rapid diagnosis and antiviral management is essential for optimizing outcomes and reducing secondary bacterial infections, particularly given the narrow therapeutic window for antiviral efficacy. Recognition of high-risk populations requiring prophylaxis and vaccination represents critical preventive medicine competency for board examination and clinical practice.

Influenza virions are enveloped RNA viruses approximately 80–120 nm in diameter, with two critical surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA). HA binds to sialic acid receptors (α-2,6 and α-2,3 linkages) on respiratory epithelial cells, mediating viral attachment and fusion with host cell membranes through pH-dependent conformational changes in the endosomal compartment. This receptor specificity determines host tropism: human-adapted strains preferentially bind α-2,6 sialic acids on upper respiratory epithelium, while avian strains recognize α-2,3 linkages, explaining the zoonotic barrier. Once internalized, the segmented negative-sense RNA genome (8 segments encoding 11 proteins) is released into the cytoplasm and transported to the nucleus for replication.

Following uncoating, viral RNA-dependent RNA polymerase complex (composed of PB1, PB2, and PA subunits) synthesizes complementary RNA strands and progeny viral RNA within the nucleus. Neuraminidase enzymatically cleaves sialic acid receptors from infected and neighboring cells, facilitating viral budding and spread to adjacent respiratory epithelial cells. The viral NS1 protein actively suppresses interferon-β and interferon-α production through multiple mechanisms: inhibition of RIG-I-like receptor signaling, blocking of JAK-STAT pathway phosphorylation, and degradation of RIG-I itself, thereby creating an immunologically permissive environment during the critical first 2–3 days of infection. This interferon antagonism represents a key determinant of viral virulence; highly pathogenic strains produce more potent NS1 proteins. Antigenic drift (point mutations in HA and NA genes) occurs continuously and allows viral escape from previously acquired immunity, explaining the need for annual vaccination. Antigenic shift, occurring through reassortment of genome segments when multiple influenza strains simultaneously infect a single cell, generates pandemic strains with novel HA or NA antigens against which the population has minimal immunity.

Viral replication is concentrated in ciliated columnar epithelial cells lining the trachea and bronchi, with peak viral shedding occurring 24–48 hours before symptom onset and continuing 5–7 days in immunocompetent hosts (up to weeks in immunocompromised individuals). Direct cytolytic effects from viral replication and budding result in loss of ciliated epithelium, with sloughed apoptotic epithelial cells and viral particles visible in respiratory secretions. This epithelial destruction impairs mucociliary clearance and disrupts the physical barrier, creating vulnerability to secondary bacterial superinfection by Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pneumoniae, and Haemophilus influenzae. The epithelial damage triggers a robust innate immune response: recruited macrophages and neutrophils produce excessive IL-6, TNF-α, and IL-8, contributing to systemic inflammation and the characteristic constitutional symptoms. In severe influenza, dysregulated inflammatory responses—rather than direct viral cytopathology—drive acute respiratory distress syndrome (ARDS), characterized by increased alveolar-capillary permeability, pulmonary edema, and impaired gas exchange.

Although influenza is primarily a respiratory pathogen, viral proteins and inflammatory mediators enter the circulation, explaining systemic symptoms including fever (from IL-1 and TNF-α-mediated hypothalamic thermoregulation), myalgias (from IL-1β and TNF-α effects on muscle nociceptors), and fatigue (from global inflammatory state and metabolic derangements). Viral neuraminidase has been detected in cardiac tissue and neuronal cells in severe cases, contributing to myocarditis and encephalitis in rare instances. The profound immunosuppression following acute influenza—characterized by impaired IL-2 production, reduced NK cell activity, and decreased dendritic cell antigen presentation—explains the increased susceptibility to secondary infections and reactivation of latent pathogens (particularly tuberculosis) in the weeks following acute infection. Pregnancy-associated changes in cell-mediated immunity (shift toward Th2 response) enhance susceptibility to severe influenza, with hospitalization rates 4–5 fold higher in pregnant women compared to non-pregnant controls.

Influenza A is responsible for seasonal epidemics and all documented pandemics in the modern era. Subtypes are classified by HA and NA combinations (e.g., H1N1, H3N2); currently circulating human strains include seasonal H1N1 and H3N2. Influenza A infects humans, birds, swine, horses, and other mammals, with avian influenza reservoir serving as ultimate source for pandemic strains. The 2009 H1N1 pandemic strain ([H1N1]pdm09) contained genetic material from avian, swine, and human influenza sources—a quadruple reassortant—demonstrating the pandemic potential of zoonotic spillover events. High-pathogenicity avian influenza (HPAI) H5N1 and emerging H7N9 strains, though currently inefficiently transmitted between humans, carry significant mortality risk (case fatality rate 30–50%) when human infection does occur.

Influenza B causes seasonal epidemics, typically arriving slightly later in the season than influenza A, and affects primarily children and young adults due to age-related immunity patterns. No known animal reservoir; human-to-human transmission only. Historically less frequent cause of pandemic disease, though capable of causing severe illness and death. Two distinct lineages (Yamagata and Victoria) have circulated since 2002, complicating vaccine formulation decisions.

Causes sporadic infections and minor outbreaks, typically in children; rarely results in severe disease or epidemiologic significance sufficient for vaccine inclusion.

Influenza is characterized by abrupt onset of systemic and respiratory symptoms, often described by patients as "sudden" compared to the gradual symptom development of common colds. The prodrome typically lasts only 1–2 hours before rapid progression to full symptomatology, distinguishing influenza from rhinoviral infections. The cardinal symptom constellation—fever (typically 38.5–40°C), myalgias (particularly in lower back and lower extremities), headache (often frontal), and fatigue—occurs in >90% of symptomatic infections and results from systemic inflammatory cytokine response rather than direct viral dissemination.

Fever onset is abrupt (rather than gradual) and often reaches peak temperature within 24 hours of symptom onset. The fever typically lasts 3–5 days, though may persist longer in severe cases or older patients. Associated with fever are profound myalgias affecting primarily large muscles of the back, thighs, and legs; patients often describe inability to walk due to leg pain. Malaise and fatigue are severe and disproportionate to the degree of respiratory involvement—a key distinguishing feature from most other upper respiratory infections. Headache occurs in 40–60% of cases and is often described as bilateral, frontal, or retroorbital. Chills accompanying fever are prominent.

Despite systemic symptoms' prominence, respiratory symptoms may be initially absent or minimal, emerging 1–2 days after systemic symptoms. When present, patients report cough (usually dry initially, later productive), sore throat, nasal congestion, and rhinorrhea. Dyspnea indicates lower respiratory tract involvement and is concerning for pneumonia or severe disease. The cough, characteristically dry and nonproductive early, can persist 2–3 weeks following resolution of fever ("post-viral cough"). Sore throat is typically mild compared to acute pharyngitis from Group A Streptococcus.

Surprisingly, physical examination is often unremarkable given the severity of symptoms reported. Fever is the most consistent finding. Pharyngeal examination may reveal mild erythema without exudate (distinguishing from streptococcal pharyngitis) and absence of significant lymphadenopathy. Nasal mucosa may appear erythematous and edematous. Lung auscultation is frequently clear in uncomplicated influenza, despite patient's complaints of cough and dyspnea; presence of crackles, wheezes, or consolidative findings suggests secondary bacterial pneumonia or primary viral pneumonia. Conjunctival injection occurs in minority of cases. Rash is distinctly uncommon and suggests alternative diagnosis (measles, dengue, or other etiology).

Older adults often present with atypical or subdued symptoms; fever may be absent despite significant infection, replaced by acute functional decline, delirium, or exacerbation of underlying chronic conditions. Patients with underlying COPD may present primarily with dyspnea and bronchial hyperresponsiveness rather than classic systemic symptoms. Immunocompromised hosts may have prolonged viral shedding (extending weeks) without clearance, leading to protracted mild symptoms rather than acute presentation.

Influenza can involve the larynx (laryngotracheobronchitis or "croup"), particularly in young children, presenting with barky, seal-like cough and stridor; more common with parainfluenza but well-described with influenza.

During documented community influenza circulation (influenza season), the clinical diagnosis of influenza can be reasonably assumed in patients presenting with acute fever and systemic symptoms (particularly myalgias and headache) with respiratory tract symptoms. However, definitive diagnosis requires microbiological confirmation, particularly for hospitalized patients, epidemiologically important cases, and immunocompromised hosts in whom diagnostic testing guides management and infection control decisions. Absence of upper respiratory prodrome and presence of myalgias and systemic symptoms make influenza more likely than rhinoviral or coronavirus infections.

Rapid molecular assays (nucleic acid amplification tests including RT-PCR and isothermal amplification) represent gold-standard diagnostic testing, with sensitivities 90–95% and specificities >95% when performed within first 3–4 days of symptom onset. These tests can be completed in 15–45 minutes depending on platform used. Abbott BinaxNOW and Quidel Sofia are commonly used point-of-care molecular assays providing rapid results. Sensitivity decreases with time from symptom onset; samples collected >4 days after illness onset have substantially reduced sensitivity. Respiratory specimens (nasopharyngeal swabs preferred over nasal swabs; throat swabs less sensitive) should be collected within first 3–4 days for optimal sensitivity.

Rapid influenza immunochromatographic tests (antigen detection) have lower sensitivity (40–70%) and specificity (90–95%) compared to molecular assays but provide results in 10–15 minutes; negative result does not exclude influenza if clinical suspicion is high. Direct fluorescent antibody (DFA) staining of respiratory epithelial cells has 60–90% sensitivity and 95%+ specificity but requires trained personnel and is rarely performed in modern practice. Viral culture on MDCK cells takes 3–10 days and is insensitive but can be useful for surveillance and resistance testing; not recommended for acute diagnosis. Serology (acute and convalescent paired sera showing 4-fold or greater rise in antibody titer) is retrospective and not useful for acute management.

In resource-limited settings or when rapid testing unavailable, the following clinical criteria suggest influenza during documented community circulation:

Absence of laboratory confirmation does not preclude antiviral treatment initiation if clinical suspicion is high and patient meets risk criteria for severe disease.

Chest X-ray in uncomplicated influenza is often normal or shows only hyperinflation. In complicated disease: